Core Viewpoint - Tengsheng Bo Pharmaceutical-B (02137) has seen a significant stock increase of over 8%, currently trading at HKD 2.28 with a transaction volume of HKD 24.33 million [1] Group 1: Company Overview - Tengsheng Bo Pharmaceutical focuses on infectious diseases and central nervous system disorders, advancing a product pipeline that includes multiple unique drug candidates [1] Group 2: Recent Developments - Guojin Securities has released a report highlighting several upcoming milestones for Tengsheng Bo Pharmaceutical related to Elebsiran, including: - The ENSURE study's fourth cohort: 48-week treatment completion data to be published at EASL 2025 - The ENSURE study's first to third cohorts: 24-week follow-up data published at EASL 2025 - The ENSURE study's fourth cohort: 24-week follow-up data - The ENRICH study: treatment completion data [1]
港股异动 | 腾盛博药-B(02137)再涨超8% Elebsiran近期迎来多项读数里程碑